Skip to content

BridgeBio Pharma

US · BBIO #1254 by market cap Listed 2019
76.03 -2.15 -2.75%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Valuation each multiple against its own 5-year range

P/B ratio -5.69 Cheap vs history 22nd percentile
5-year average -4.10
P/E ratio -25.09 Cheap vs history 1st percentile
5-year average -9.90 · forward -38.67
P/S ratio 15.66 Cheap vs history 6th percentile
5-year average 126.34 · forward 10.08 · #211 of 392 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
BridgeBio Pharma (BBIO) 14.81B -25.09 -5.69 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value85.00 Economic moatNone UncertaintyVery High Capital allocationStandard

Trading 11.8% below Morningstar's fair value estimate.

Analyst note

BridgeBio reported $353 million in sales, up roughly 193% year over year, and ahead of FactSet consensus. Attruby (for ATTR-CM) sales contributed $253 million, up roughly 14% sequentially, reflecting physician uptake and new-patient adoption. Shares are up roughly 6% on Oct. 30.

Why it matters: We continue to view Attruby uptake favorably as the only near-complete stabilizer of transthyretin approved in the US for ATTR-CM. Management noted that first-line starts are emerging as the primary growth driver, so while the exceptionally strong launch trajectory may normalize over time, we believe Attruby's efficacy profile and expanding physician awareness should continue to underpin adoption. This quarter saw a series of positive clinical updates for BridgeBio's three late-stage assets, BBP-418 (for limb-girdle muscular dystrophy), infigratinib (for achondroplasia), and encaleret (for ADH1). In our view, these developments reinforce their differentiated clinical profiles and increase confidence in their potential launches. A one-time $75 million milestone tied to Beyonttra (for ATTR-CM) sales accounted for much of the revenue outperformance The company is on track to exceed $1 billion in revenue this year. 

The bottom line: We maintain our fair value estimate of $85 for no-moat BridgeBio. Recent encouraging clinical updates across BridgeBio's late-stage pipeline this quarter further strengthens the outlook for its upcoming commercial launches and reduces clinical risk ahead of potential approvals. BridgeBio's late-stage assets face FDA decisions over the next two quarters, beginning with BBP-418 in November, infigratinib in February, and encaleret in May. We assign them approval rates of 95%, 90%, and 90%, respectively. Pending upcoming launches, we continue to anticipate elevated operating expenses and associated commercial risk as these potential launches approach, and we highlight our Very High Uncertainty Rating.

Fair value

We maintain our fair value estimate of $85 per share for no-moat BridgeBio. We assign a 90% probability of approval to infigratinib, and we have a positive outlook for this achondroplasia candidate based on positive phase 3 trial results. Bridgebio submitted regulatory filings in the US and anticipates a launch in mid-2027. Management plans to submit a Marketing Authorization Application for achondroplasia to the European Medicines Agency in the fourth quarter of 2026.

Our valuation largely rests on the commercial success of Attruby. We estimate this drug could generate global revenue of approximately $4.5 billion by 2035, with the US accounting for $3.6 billion in sales. Attruby is at the centerpiece of the firm’s growth strategy, so it is crucial for it to achieve strong patient uptake.

Other drugs in BridgeBio’s late-stage pipeline also have strong growth potential. We model that encaleret could achieve peak sales of nearly $600 million by 2035, assuming it captures around 20% of the patient market. For BBP-418 and low-dose infigratinib, which we anticipate could launch commercially in 2027, we estimate probability-weighted 2035 sales of nearly $300 million and $1.2 billion, respectively. Overall, on a probability-weighted basis, the company’s pipeline could contribute roughly $2.1 billion in revenue by 2035.

We anticipate that product costs will be roughly 10% of total revenue, resulting in a gross margin of about 90%. As the company’s pipeline advances into late-stage trials, we anticipate its R&D costs will continue to grow, and selling, general, and administrative expenses are expected to increase as drug candidates approach commercialization. As revenue grows over our 10-year forecast period, R&D expenses and SG&A expenses will scale as a percentage of sales. We assume a 9% cost of equity for BridgeBio, which is consistent with the other emerging biotech companies.

Economic moat

We don’t believe BridgeBio has an economic moat. The company’s key drug is Attruby (for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis, or ATTR-CM). The rest of its pipeline remains unapproved, and Attruby’s own commercial trajectory is still relatively early in a crowded ATTR-CM market. BridgeBio’s focus on high unmet medical needs and its recent strategic partnerships are positive indicators, but we need to see maintained cash flow and successful commercialization across multiple products before considering a narrow moat rating.

Through its 2021 merger with Eidos Therapeutics, BridgeBio gained full rights to acoramidis (Attruby), a potential best-in-class therapy for transthyretin amyloidosis, a rare heart disease caused by misfolded TTR protein accumulating in the heart muscle. Bayer holds European rights, and AstraZeneca holds Japanese rights, while BridgeBio retains the US opportunity. Attruby is central to our valuation, accounting for nearly 70% of our 2035 revenue forecast, so any long-term safety issues or superior competitor data would significantly impair the firm’s value. This concentration risk, and the threat of substantial value destruction it implies, drives our no moat rating.

BridgeBio's main competitor in ATTR amyloidosis is Pfizer's Vyndaqel/Vyndamax (tafamidis), the only other approved TTR stabilizer. Both tafamidis and acoramidis (Attruby) bind and stabilize the TTR protein, preventing it from forming amyloid deposits and slowing disease progression. Their safety profiles appear similar, but in the phase 3 ATTRibute-CM trial, acoramidis achieved higher serum TTR levels, a marker associated with lower mortality and hospitalization risk in ATTR-CM. This is a cross-trial comparison, since the two drugs have not been tested head-to-head.

A newer class, TTR silencers, reduces TTR production rather than stabilizing the protein. Alnylam's Amvuttra (vutrisiran) is the key approved entrant. However, because acoramidis reached the market first as a lower-cost stabilizer with strong efficacy, we think silencers will struggle to displace stabilizers as the standard of care. Combining a stabilizer with a silencer will likely remain cost-prohibitive at least until Vyndaqel's patent expires in 2031.

Given these dynamics and a growing pool of diagnosed patients, driven by greater disease awareness and noninvasive diagnostics, we believe Attruby could capture significant share among newly diagnosed and inadequately managed patients.

A key risk to Attruby’s market share gains is generic entry once Pfizer’s Vyndaqel/Vyndamax patents expire, in 2026 in Europe and 2031 in the United States. BridgeBio appears to be positioning itself to build patient loyalty ahead of and during the interim period before generics become available.

BridgeBio is also advancing other late-stage pipeline candidates. Encaleret, an investigational oral therapy for ADH1, would compete with Ascendis’ injectable Yorvipath, with oral administration as its main advantage. BridgeBio’s low-dose infigratinib targets FGFR-driven conditions including achondroplasia and hypochondroplasia. In February 2026, BridgeBio reported positive phase 3 top-line results, and if approved, it would compete with BioMarin’s Voxzogo, the first approved achondroplasia drug, with oral dosing as its key differentiator against Voxzogo’s daily injections. BridgeBio’s BBP-418 could become the first oral therapy for LGMD2I/R9, a rare muscle-degeneration disorder, and faces minimal competition given how early-stage alternative treatments remain.

A critical factor in BridgeBio’s valuation is its ability to advance pipeline drugs to market. Nulibry, approved in 2021 for the rare disorder molybdenum cofactor deficiency type A, had its global rights sold to Sentynl in 2022 for a modest $10 million upfront; BridgeBio now earns only tiered royalties and milestones on it, illustrating how commercial execution of pipeline candidates remains essential to the firm’s growth and market position.

We are also concerned about BridgeBio’s heavy dependence on strategic collaborations for the marketing and commercialization of its product candidates, as demonstrated by the issues with Truseltiq. Despite receiving FDA approval in 2021 for bile duct cancer, Truseltiq was discontinued after pharmaceutical company Helsinn terminated its commercialization agreement. The FDA approval was also withdrawn because BridgeBio was unable to fund and complete the required postmarketing studies to verify the clinical benefits of the drug. Similarly, the success of Attruby is closely tied to BridgeBio's collaboration with Bayer, a German pharmaceutical company. According to their recent agreement, Bayer has been granted an exclusive license to commercialize Attruby as a treatment for ATTR-CM in Europe. While this partnership offers BridgeBio a lucrative deal, including up to $310 million in upfront and near-term milestone payments and royalty percentages starting in the low 30s, the ultimate success of Attruby in Europe will be contingent upon Bayer’s ability to effectively market and sell the drug.

Overall, we think the company has several promising candidates that could one day support a moat, but the uncertainty around their development is too high to warrant a narrow moat at this time. We currently give the company's late-stage clinical drug candidates probabilities of approval of 90%, with these therapies estimated to reach the market in 2027.

Bull case

The successful commercialization of Attruby could establish BridgeBio as a key player in the ATTR-CM market, significantly improving its path to profitability.

BridgeBio’s pipeline targets high unmet patient needs, positioning the company’s products for strong market adoption upon receiving regulatory approval.

Partnerships with pharmaceutical companies provide milestone payments and economic benefits, offsetting clinical development costs and supporting BridgeBio’s financial stability and market entry.

Bear case

BridgeBio has historically faced challenges in developing pipeline candidates and bringing them to market.

BridgeBio's valuation relies on the commercialization of Attruby, but the drug's full potential may be undermined by tafamidis’ patent extension, introduction of generic alternatives, and other branded competition.

While BridgeBio targets several rare genetic disorders—including amyloidosis, achondroplasia, and ADH1—it faces competition from other companies advancing next-generation therapies in these disease areas.

By Rachel Elfman, Rashmi Nair

Quote time 2026-11-20 20:01:24 · For reference only, not investment advice and not tailored to your situation.

BridgeBio Pharma discussion 0 comments

Add a comment